| 1 |
Haraldsson B. A new era of podocyte-targeted therapy for proteinuric kidney disease [J]. N Engl J Med,2013,369(25):2453-2454.
|
| 2 |
Clevers H,Nusse R. Wnt/beta-catenin signaling and disease [J].Cell,2012,149(6):1192-1205.
|
| 3 |
Sharma S,Sirin Y,Susztak K. The story of Notch and chronic kidney disease [J]. Curr Opin Nephrol Hypertens,2011,20(1):56-61.
|
| 4 |
Kato H,Gruenwald A,Suh JH, et al. Wnt/beta-catenin pathway in podocytes integrates cell adhesion,differentiation,and survival[J].J Biol Chem,2011,286(29):26003-26015.
|
| 5 |
Dai C, Stolz DB, Kiss LP, et al. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria [J]. J Am Soc Nephrol,2009,20(9):1997-2008.
|
| 6 |
Cox SN,Sallustio F,Serino G, et al. Altered modulation of Wntbeta-catenin and PI3K/Akt pathways in IgA nephropathy [J].Kidney Int,2010,78(4):396-407.
|
| 7 |
Heikkila E, Juhila J, Lassila M, et al. beta-Catenin mediates adriamycin-induced albuminuria and podocyte injury in adult mouse kidneys [J]. Nephrol Dial Transplant,2010,25(8):2437-2446.
|
| 8 |
Lin CL,Wang JY,Ko JY,et al. Dickkopf-1 promotes hyperglycemiainduced accumulation of mesangial matrix and renal dysfunction[J]. J Am Soc Nephrol,2010,21(1):124-135.
|
| 9 |
Murea M,Park JK,Sharma S,et al. Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function [J]. Kidney Int,2010,78(5):514-522.
|
| 10 |
Sharma M,Callen S,Zhang D,et al. Activation of Notch signaling pathway in HIV-associated nephropathy [J]. AIDS,2010,24(14):2161-2170.
|
| 11 |
Lasagni L, Ballerini L, Angelotti ML, et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders[J]. Stem Cells,2010,28(9):1674-1685.
|
| 12 |
Niranjan T,Bielesz B,Gruenwald A,et al. The Notch pathway in podocytes plays a role in the development of glomerular disease [J].Nat Med,2008,14(3):290-298.
|
| 13 |
Waters AM,Wu MY,Onay T,et al. Ectopic notch activation in developing podocytes causes glomerulosclerosis [J]. J Am Soc Nephrol,2008,19(6):1139-1157.
|
| 14 |
Ahn S H,Susztak K. Getting a notch closer to understanding diabetic kidney disease [J]. Diabetes,2010,59(8):1865-1867.
|
| 15 |
Lin CL,Wang FS,Hsu YC,et al. Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy [J]. Diabete,2010,59(8):1915-1925.
|
| 16 |
Ohse T, Pippin JW, Chang AM, et al. The enigmatic parietal epithelial cell is finally getting noticed: a review [J]. Kidney Int,2009,76(12):1225-1238.
|
| 17 |
Ronconi E, Sagrinati C, Angelotti ML, et al. Regeneration of glomerular podocytes by human renal progenitors [J]. J Am Soc Nephrol,2009,20(2):322-332.
|
| 18 |
Kato H,Susztak K. Repair problems in podocytes:Wnt,Notch,and glomerulosclerosis [J]. Semin Nephrol,2012,32(4):350-356.
|
| 19 |
Scott RP,Hawley SP,Ruston J, et al. Podocyte-specific loss of Cdc42 leads to congenital nephropathy [J]. J Am Soc Nephrol,2012,23(7):1149-1154.
|
| 20 |
Blattner SM,Hodgin JB,Nishio M,et al. Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury [J]. Kidney Int,2013,84(5):920-930.
|
| 21 |
Wang L,Ellis MJ,Gomez JA,et al. Mechanisms of the proteinuria induced by Rho GTPases [J]. Kidney Int, 2012, 81 (11):1075-1085.
|
| 22 |
Zhu L,Jiang R,Aoudjit L,et al. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis [J]. J Am Soc Nephrol,2011,22(9):1621-1630.
|
| 23 |
Jeruschke S,Buscher AK,Oh J,et al. Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling [J]. PLoS One, 2013, 8 (2):e55980.
|
| 24 |
Inoki K,Mori H,Wang J,et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice[J].J Clin Invest,2011,121(6):2181-2196.
|
| 25 |
Gee HY,Saisawat P,Ashraf S,et al. ARHGDIA mutations cause nephrotic syndrome via defective Rho GTPase signaling [J]. J Clin Invest,2013,123(8):3243-3253.
|
| 26 |
Ingelfinger JR. MYO1E,focal segmental glomerulosclerosis, and the cytoskeleton [J]. N Engl J Med,2011,365(4):368-369.
|
| 27 |
Krendel M,Kim SV,Willinger T,et al. Disruption of myosin 1e promotes podocyte injury [J]. J Am Soc Nephrol,2009,20(1):86-94.
|
| 28 |
Chase SE, Encina CV, Stolzenburg LR, et al. Podocyte-specific knockout of myosin 1e disrupts glomerular filtration [J]. Am J Physiol Renal Physiol,2012,303(7): F1099-1106.
|
| 29 |
Bi J,Chase SE,Pellenz CD,et al. Myosin 1e is a component of the glomerular slit diaphragm complex that regulates actin reorganization during cell-cell contact formation in podocytes [J]. Am J Physiol Renal Physiol,2013,305(4): F532-544.
|
| 30 |
Sachs N, Sonnenberg A. Cell-matrix adhesion of podocytes in physiology and disease [J]. Nat Rev Nephrol,2013,9 (4):200-210.
|
| 31 |
Wei C,Moller CC,Altintas MM,et al. Modification of kidney barrier function by the urokinase receptor [J]. Nat Med, 2008, 14(1):55-63.
|
| 32 |
Wei C,El Hindi S,Li J,et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis[J]. Nat Med,2011,17(8):952-960.
|
| 33 |
Maas RJ,Wetzels JF,Deegens JK. Serum-soluble urokinase receptor concentration in primary FSGS [J]. Kidney Int, 2012, 81(10):1043-1044.
|
| 34 |
Parikh SM.Circulating mediators of focal segmental glomerulosclerosis: soluble urokinase plasminogen activator receptor in context [J]. Am J Kidney Dis,2012,59(3):336-339.
|
| 35 |
Jefferson JA,Shankland SJ. Has the circulating permeability factor in primary FSGS been found [J]? Kidney Int, 2013, 84 (2):235-238.
|
| 36 |
Huang J,Liu G,Zhang YM,et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis [J]. Kidney Int, 2013, 84(2):366-372.
|
| 37 |
Zhang B, Xie S,Shi W,et al. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria [J].Nephrol Dial Transplant,2012,27(5):1746-1755.
|
| 38 |
Zhang B,Shi W,Ma J,et al. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury [J]. J Mol Med (Berl), 2012, 90 (12):1407-1420.
|
| 39 |
Li R,Zhang L,Shi W,et al. NFAT2 mediates high glucose-induced glomerular podocyte apoptosis through increased Bax expression [J].Exp Cell Res,2013,319(7):992-1000.
|
| 40 |
Zhang L,Li R,Shi W,et al. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice [ J]. Br J Pharmacol,2013,170(2):426-439.
|
| 41 |
Zhu L,Qi XY,Aoudjit L,et al. Nuclear factor of activated T cells mediates RhoA-induced fibronectin upregulation in glomerular podocytes [J]. Am J Physiol Renal Physiol, 2013, 304 (7):F849-862.
|
| 42 |
Panichi V, Migliori M, Taccola D, et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats [J]. Kidney Int,2001,60(1):87-95.
|
| 43 |
Wang Y,Zhou J,Minto AW,et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy [J]. Kidney Int,2006,70(5):882-891.
|
| 44 |
Zhang Z,Sun L,Wang Y,et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy [J]. Kidney Int, 2008, 73(2):163-171.
|
| 45 |
Xiao H,Shi W,Liu S,et al. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Aktsignaling pathway [J]. Am J Nephrol,2009,30(1):34-43.
|
| 46 |
Xiao HQ,Shi W,Liu SX,et al. Podocyte injury is suppressed by 1,25-dihydroxyvitamin D via modulation of transforming growth factorbeta 1/bone morphogenetic protein-7 signalling in puromycin aminonucleoside nephropathy rats[J]. Clin Exp Pharmacol Physiol,2009,36(7):682-689.
|
| 47 |
Ma J,Zhang B,Liu S,et al. 1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria [J]. PLoS One,2013,8(5): e64912.
|
| 48 |
de Zeeuw D,Agarwal R,Amdahl M,et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes ( VITAL study): a randomised controlled trial [J]. Lancet,2010,376(9752):1543-1551.
|
| 49 |
Sonneveld R,Ferre S,Hoenderop JG, et al. Vitamin D downregulates TRPC6 expression in podocyte injury and proteinuric glomerular disease [J]. Am J Pathol,2013,182(4):1196-1204.
|
| 50 |
Tossidou I,Schiffer M. TGF-beta/BMP pathways and the podocyte[J]. Semin Nephrol,2012,32(4):368-376.
|
| 51 |
Jung KY, Chen K, Kretzler M, et al. TGF-beta1 regulates the PINCH-1-integrin-linked kinase-alpha-parvin complex in glomerular cells [J]. J Am Soc Nephrol,2007,18(1):66-73.
|
| 52 |
Niranjan T,Murea M,Susztak K. The pathogenic role of Notch activation in podocytes[J]. Nephron Exp Nephrol,2009,111(4):e73-79.
|
| 53 |
Wang D,Dai C,Li Y,et al. Canonical Wnt/beta-catenin signaling mediates transforming growth factor-beta1-driven podocyte injury and proteinuria [J]. Kidney Int,2011,80(11):1159-1169.
|
| 54 |
Nguyen TQ,Roestenberg P,van Nieuwenhoven FA,et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy [J]. J Am Soc Nephrol,2008,19(11):2098-2107.
|
| 55 |
Mizushima N,Levine B,Cuervo AM,et al. Autophagy fights disease through cellular self-digestion [J]. Nature, 2008, 451(7182):1069-1075.
|
| 56 |
Hartleben B, Godel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice [J]. J Clin Invest, 2010, 120(4):1084-1096.
|
| 57 |
Narita M,Young AR,Arakawa S,et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes [J]. Science, 2011,332(6032):966-970.
|
| 58 |
Godel M,Hartleben B,Herbach N,et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice [J]. J Clin Invest,2011,121(6):2197-2209.
|
| 59 |
Fang L,Zhou Y,Cao H,et al. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury [J]. PLoS One,2013,8(4): e60546.
|
| 60 |
Letavernier E,Bruneval P,Mandet C,et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo [J]. Clin J Am Soc Nephrol,2007,2(2):326-333.
|
| 61 |
Munivenkatappa R,Haririan A,Papadimitriou JC,et al. Tubular epithelial cell and podocyte apoptosis with de novo sirolimus based immunosuppression in renal allograft recipients with DGF [J].Histol Histopathol,2010,25(2):189-196.
|
| 62 |
Stylianou K,Petrakis I,Mavroeidi V,et al. Rapamycin induced ultrastructural and molecular alterations in glomerular podocytes in healthy mice [ J]. Nephrol Dial Transplant, 2012, 27 (8):3141-3148.
|
| 63 |
Cina DP,Onay T,Paltoo A,et al. Inhibition of MTOR disrupts autophagic flux in podocytes [J]. J Am Soc Nephrol, 2012, 23(3):412-420.
|
| 64 |
Cina DP,Onay T,Paltoo A,et al. MTOR regulates autophagic flux in the glomerulus [J]. Autophagy,2012,8(4):696-698.
|